RxDoctor Payments Data

Vigyan Bang, MD

Cardiovascular Disease · Joplin, MONPI 1790199727

Payments from drug & device makers

$14,363in general payments, 2019–2025

Across 142 payments — averaging $101.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Edwards Lifesciences$3K
  • Abbott$2K
  • Medtronic$2K
  • Abiomed$517
  • Jenavalve Technology, Inc.$219
  • plus $581 from 8 others

What the payments were for

  • Consulting fees$2192%
  • Grants$1,69512%
  • Travel & lodging$5,97442%
  • Food & beverage$6,01842%
  • Education$4553%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,363 in reported general payments places this provider in the 75th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$347,942
Medicare patients
1,302
Services billed
4,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban366$335,611
JardianceEmpagliflozin253$217,956
EntrestoSacubitril/Valsartan244$206,455
XareltoRivaroxaban176$166,345
Repatha SureclickEvolocumab54$39,979
BrilintaTicagrelor25$14,717
FarxigaDapagliflozin Propanediol14$12,770
Metoprolol Succinate951$9,417
Prasugrel Hcl47$8,123
Atorvastatin Calcium533$3,610
Isosorbide Mononitrate ErIsosorbide Mononitrate279$3,023
ClopidogrelClopidogrel Bisulfate344$2,519
Amlodipine Besylate514$2,444
Valsartan154$2,296
Ranolazine ErRanolazine30$2,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$64$27,48739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →